Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027

  Address - Germany

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 99891150

  Document Type - Tender Notices

Description - Description: Scope of procurementBrief descriptionSection 130a paragraph 8 of the Social Code Book V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the drugs to be dispensed at the expens e of the statutory health insurance companies. With regard to the relevant legal provisions for the award of public contracts, a regular process of active substance-related, formal award procedures takes place by DAK-Gesundheit in accordance with the regulations of Part 4 of the GWB. For drugs for the above-mentioned active substance, mepolizumab, ATC R03DX09, which are to be specified by the bidder in Annex 2 to the contract, DAK-Gesundheit inte

Gt Ref Id - 99891150

Deadline - Dec 04, 2026